Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomized controlled trial
Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would b...
Wedi'i Gadw mewn:
Prif Awduron: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Fformat: | Technical Report |
Iaith: | en_US |
Cyhoeddwyd: |
Lancet Infect Dis 2016
2016
|
Pynciau: | |
Mynediad Ar-lein: | http://103.69.126.140:8080/handle/123456789/818 |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Crynodeb: | Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would be superior to the cephalosporin ceftriaxone in treating enteric fever. |
---|